Search

everythinglearnresearchcommunity

for

Search:↓

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Ruxolitinib cream may help treat severe hair loss in children.

Alopecia areata is an autoimmune disease causing hair loss, and targeting macrophages may help treat it.

NXC736 significantly reduced hair loss in mice with alopecia areata.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

New treatments for alopecia areata show promise in improving hair loss outcomes.

BTNL2 helps protect hair follicles from immune attacks, which could aid in treating alopecia areata.

The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.

Thymoma with alopecia areata may be linked to abnormal immune cells.

Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Reducing CD8+ T cell growth can stabilize alopecia areata.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Modulating the BTNL2 pathway can prevent hair loss in mice.

IL-27 can prevent hair loss in alopecia areata.

A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.

Being allergic to linalool, a common fragrance ingredient, might contribute to developing frontal fibrosing alopecia.

ILC1-like cells may contribute to hair loss in alopecia areata.

Mitochondrial stress can lead to atopic dermatitis.

ILC1-like cells can cause alopecia areata by themselves.

ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.

The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.

Lichen Planopilaris causes irreversible hair loss due to immune attacks on hair stem cells, but modulating PPAR-γ might help treat it.

Vitiligo treatments include JAK inhibitors, UVB phototherapy, and dietary changes, with emotional support being important.

Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.